ANAB (AnaptysBio) E10: $-3.36 (As of Mar. 2026)


ANAB AnaptysBio Inc ANAB
67 GF Score
Price $59.62
GF Value $61.87
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is AnaptysBio E10?

AnaptysBio ANAB +1.95% 67 E10 is $-3.36 as of Mar. 2026. GuruFocus rates ANAB with a GF Score™ of 67/100 and a GF Value™ of $61.87 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AnaptysBio's adjusted earnings per share data for the three months ended in Mar. 2026 was $-1.840. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-3.36 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-25), AnaptysBio's current stock price is $59.6225. AnaptysBio's E10 for the quarter that ended in Mar. 2026 was $-3.36. AnaptysBio's Shiller PE Ratio of today is .


AnaptysBio  (NAS:ANAB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AnaptysBio E10 Related Terms


AnaptysBio E10 Historical Data

* Premium members only.

The historical data trend for AnaptysBio's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio E10 Chart

AnaptysBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -3.04 -3.13

AnaptysBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.21 -3.37 -3.33 -3.13 -3.36

ANAB vs VIR, GHRS, INVA: E10 Comparison

For the Biotechnology subindustry, AnaptysBio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Shiller PE Ratio falls into.


ANAB
67GF Score
AnaptysBio Inc ANAB
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnaptysBio E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AnaptysBio's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.84/330.2130*330.2130
=-1.840

Current CPI (Mar. 2026) = 330.2130.

AnaptysBio Quarterly Data

per share eps CPI Adj_EPS
201606 0.012 241.018 0.016
201609 -0.079 241.428 -0.108
201612 -0.235 241.432 -0.321
201703 -0.750 243.801 -1.016
201706 -0.130 244.955 -0.175
201709 -0.450 246.819 -0.602
201712 -0.300 246.524 -0.402
201803 -0.630 249.554 -0.834
201806 -0.570 251.989 -0.747
201809 -0.660 252.439 -0.863
201812 -0.640 251.233 -0.841
201903 -0.820 254.202 -1.065
201906 -0.890 256.143 -1.147
201909 -1.150 256.759 -1.479
201912 -0.750 256.974 -0.964
202003 -0.300 258.115 -0.384
202006 -0.790 257.797 -1.012
202009 -0.870 260.280 -1.104
202012 1.230 260.474 1.559
202103 -0.660 264.877 -0.823
202106 -0.020 271.696 -0.024
202109 -0.240 274.310 -0.289
202112 -1.180 278.802 -1.398
202203 -1.310 287.504 -1.505
202206 -1.150 296.311 -1.282
202209 -1.180 296.808 -1.313
202212 -0.930 296.797 -1.035
202303 -1.580 301.836 -1.729
202306 -1.500 305.109 -1.623
202309 -1.410 307.789 -1.513
202312 -1.590 306.746 -1.712
202403 -1.640 312.332 -1.734
202406 -1.710 314.175 -1.797
202409 -1.140 315.301 -1.194
202412 -0.720 315.605 -0.753
202503 -1.280 319.799 -1.322
202506 -1.340 322.561 -1.372
202509 0.520 324.800 0.529
202512 1.580 324.054 1.610
202603 -1.840 330.213 -1.840

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-3.36 mean?
AnaptysBio (ANAB) has a E10 of $-3.36 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AnaptysBio and its competitors.
Is AnaptysBio's E10 too high?
AnaptysBio's current E10 is $-3.36. Overall, AnaptysBio has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's E10 compare to VIR and GHRS?
AnaptysBio's E10 of $-3.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AnaptysBio and its competitors. AnaptysBio's current E10 is $-3.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
Based on GuruFocus' analysis, AnaptysBio (ANAB) is currently considered Fairly Valued. The stock's GF Value™ is $61.87, compared to a current price of $59.62 — trading 3.6% below its estimated fair value. The current E10 is $-3.36. AnaptysBio's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For AnaptysBio (ANAB), the current E10 is $-3.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued. The current stock price of $59.62 is trading 3.6% below its estimated GF Value™ of $61.87. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for ANAB:

  • E10: $-3.36
  • GF Value™: $61.87 vs. price of $59.62 (3.6% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AnaptysBio Business Description

Other Exchanges 0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score

Get the complete analysis for ANAB

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.62
Price
$61.87
GF Value